About Circulogene Theranostics
Circulogene Theranostics is a private company based in Birmingham, Alabama. It has reported $10,940,000 raised in ten offerings on Form D since July 2015. Its chief executive is Mike Mullen.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2023 | Mar 27, 2023 | $2,000,000of $5.0M target | 1 | $2.0M | DebtRule 506(b) | Form D ↗ |
| Jul 14, 2022 | Aug 18, 2022amended Sep 1, 2022 | $2,590,000of $5.0M target | 9 | $287K | DebtRule 506(b) | Form D/A ↗2 earlier filings |
| Jan 14, 2021 | Jan 25, 2021 | $250,000of $15.0M target | 1 | $250K | DebtRule 506(b) | Form D ↗ |
| Sep 9, 2019 | Sep 17, 2019 | $330,000of $2.0M target | 6 | $55,000 | DebtRule 506(b) | Form D ↗ |
| Nov 1, 2018 | Nov 16, 2018 | $2,050,000of $3.0M target | 6 | $341K | EquityRule 506(b) | Form D ↗ |
| Jan 18, 2018 | Jan 25, 2018 | $1,035,000of $3.0M target | 6 | $172K | EquityRule 506(b) | Form D ↗ |
| Sep 7, 2017 | Sep 21, 2017 | $350,000of $700K target | 6 | $58,333 | Debt, OptionsRule 506(b) | Form D ↗ |
| Mar 16, 2017 | Mar 28, 2017 | $355,000of $800K target | 5 | $71,000 | DebtRule 506(b) | Form D ↗ |
| Sep 22, 2016 | Oct 7, 2016 | $750,000of $1.0M target | 8 | $93,750 | DebtRule 506(b) | Form D ↗ |
| May 20, 2015 | Jul 1, 2015 | $1,230,000of $3.0M target | 9 | $136K | EquityRule 506(b) | Form D ↗ |
| Total, ten offerings | $10,940,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Circulogene Theranostics's Form D filed Mar 27, 2023.
Earlier filings also listed Thomas Satterfield (director, last listed Jan 2021), Stephen Eck (director, last listed Jan 2021), Scott Rezek (executive officer, last listed Jan 2021), Robert Garvie (director, last listed Jan 2021), James Cantrell (director, last listed Jan 2021), Harold Dunn (director, last listed Jan 2021), Daniel Coleman (director, last listed Jan 2021) and Chen-Hsiung Yeh (executive officer, last listed Jan 2021).